These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-004456-39 A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca... 2012-06-01 bad-data
Ongoing 2006-004328-35 Etude de phase II de l'association CISPLATINE TOPOTECAN et CETUXIMAB chez les patientes atteintes d'un cancer épithelial du col de l'uterus avancé ou en rechute. not-yet-due
Reported results 2006-004332-79 "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sein m... 2018-09-12 due-trials
Reported results 2007-002736-28 A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old with ... 2012-01-13 due-trials
Ongoing 2007-003002-10 A multicentre phase II study, estimating the efficiency and the tolerance of RAD001 (Everolimus) , in patients with endometrial metastatic cancer resistant to a first line of chemotherapy not-yet-due
Exempt 2008-001842-19 Etude de phase I / II de l’association carboplatine et topotecan oral hebdomadaire chez des patientes atteintes de cancer du col de l’utérus métastatique ou en rechute. not-yet-due
Not reported 2008-007497-37 ESSAI EN DEUX ETAPES DE L’EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L’OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATION D... 2016-07-21 due-trials
Reported results 2009-016338-29 Essai randomisé multicentrique de phase III comparant la poursuite du traitement d’entretien par l’association bevacizumab + taxane versus remplacement par bevacizumab + exemestane chez des patientes ... 2018-09-18 due-trials
Reported results 2009-016708-21 Essai multicentrique de phase II évaluant l'efficcacité et la tolérance de l'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein mé... 2016-02-03 due-trials
Completed, but no date, and reported results 2011-002576-16 Phase 2 multicenter study to assess the safety and efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line therapy in patients who can... bad-data
Reported results 2011-006288-23 Randomized double blind placebo-controlled phase II trial of Vargatef® in addition to first line chemotherapy with interval debulking surgery in patients with adenocarcinoma of the ovary, the fallopia... 2021-11-15 due-trials
Reported results 2012-002841-39 A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapse... 2021-04-28 due-trials
Reported results 2013-001710-15 Phase II study in patient in first line for HER - metastasis breast cancer treated with eribulin and bevacizumab ESSAI DE PHASE II EVALUANT L’ASSOCIATION ÉRIBULINE (HALAVEN®) + BEVACIZUMAB (AVASTI... 2019-02-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-004027-52 Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB ? IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated... 2022-03-22 bad-data
Listed as ongoing, but also has a completion date 2015-005471-24 A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemoth... 2024-05-22 bad-data
Completed, reported early 2016-004163-39 A randomized, open-label, multicentric phase II trial of PEMBROLIZUMAB (Ketruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amenabl... 2024-03-19 not-yet-due
Completed, but no date 2018-002281-39 A GINECO phase II trial assessing the safety and efficacy of the Bevacizumab (FKB238), Olaparib (MEDI 4736) and Durvalumab combination in patients with advanced epithelial ovarian cancer in relapse: B... bad-data
Ongoing 2019-002271-34 A multicenter, pilot study evaluating immune impact and safety of nivolumab in combination with ipilimumab (immune combination) before initial RT-CT treatment for cervix cancer. COLIBRI Study Etude... not-yet-due
Ongoing 2019-002662-12 A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurr... not-yet-due
Other 2020-002260-31 Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line advanced small cell ovarian carcinoma of hypercalcemic type Etude de ... not-yet-due
Other 2020-004364-25 Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive recu... not-yet-due
Other 2021-002124-21 Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGOT-e... not-yet-due
Other 2021-004278-76 A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Ad... not-yet-due